| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 10/31/2001 | EP0703779B1 Enzyme-containing tablets and process of preparation thereof |
| 10/31/2001 | DE10027258C1 Transdermal therapeutic system, for local/systemic delivery of non-steroidal antiinflammatory agents, comprises a permeable, elastic water and air permeable backing layer and an impermeable two-phase drug-containing matrix layer |
| 10/31/2001 | DE10019154A1 Zellbindende Nukleinsäuremoleküle (Aptamere) Cell-binding nucleic acid molecules (aptamers) |
| 10/31/2001 | CN1320145A Pressure-sensitive adhesive composition and moisture-premeable pressure-sensitive adhesive tape, pressure-sensitive adhesive drug composition, and pressure-sensitive adhesive tape preparation |
| 10/31/2001 | CN1320046A Drug composition for topical administration |
| 10/31/2001 | CN1320032A Alginate capsules for use in the treatment of brain tumor |
| 10/31/2001 | CN1319615A Hard capsule containing vinyl ester and polyether polymer, its use and production process |
| 10/31/2001 | CN1319434A Magnetic medicine-carried conveying material and preparation method thereof |
| 10/31/2001 | CN1319433A Process for preparation of slow-releasing material |
| 10/31/2001 | CN1319396A Medicinal composition |
| 10/31/2001 | CN1319391A Active content contained floating form having polyacetic vinylester and polyvinyl pyrrolidone, its preparation and use |
| 10/31/2001 | CN1073978C Polyol compoistion produced by CO-spray-drying |
| 10/31/2001 | CN1073858C Stabilizer-containing live attenuated hepatitis A vaccine and its preparation |
| 10/30/2001 | US6310094 Ready-to-use esmolol solution |
| 10/30/2001 | US6310053 Complexed with an equimolar amount of a magnesium compound, and solubilized in a water miscible solvent system comprising glycerol formal and polyethylene glycol in different volumes depending on molecular weight, and a ph modifier reduction |
| 10/30/2001 | US6310047 Forming a complex of an antisense oligodeoxynucleotide and a polynuclear platinum compound, and administering the complex to cells; treating cancer; platinum diamine complexes of given formula |
| 10/30/2001 | US6310043 Using compounds which bind to toxins associated with enteric bacterial infection including pentameric toxins, for example slts, such as those from salmonella, camylobacter, e-coli |
| 10/30/2001 | US6310039 Tumor-inhibiting conjugates of proteins and polymers consisting of a suitable carrier system and cytostatic compounds |
| 10/30/2001 | US6309880 Antibodies specific for CD4-binding domain of HIV-1 |
| 10/30/2001 | US6309665 Composition with sustained release of active principle, capable of forming a microemulsion |
| 10/30/2001 | US6309663 Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents |
| 10/30/2001 | US6309653 Cholesterol ester clathrate, water-holding composition, hydrous compositions, cosmetics containing the same, and process for the preparation thereof |
| 10/30/2001 | US6309646 Derivatizing a polysaccharide with thiols, amines, or hydrazides; reacting the derivatized polysaccharide with a vinylsulfone group; reacting the product with a protein, a peptide, or a hapten |
| 10/30/2001 | US6309634 Methods of treating Parkinson's disease using recombinant adeno-associated vector (rAAV) |
| 10/30/2001 | US6309633 Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same |
| 10/30/2001 | US6309630 Non-steroidal anti-inflammatory ophthalmic suspensions |
| 10/30/2001 | US6309623 Plurality of perforated microstructures having a mean aerodynamic diameter of less than 5 mum and comprising at least one bioactive agent wherein said suspension medium comprises at least one propellant |
| 10/30/2001 | CA2220178C Dry preparations containing microbially produced oil |
| 10/30/2001 | CA2206530C Combined preparation for stimulating hair growth and optionally nail growth and skin regeneration and for preventing or combatting hair loss |
| 10/30/2001 | CA2165265C High hydroxyacid water in oil emulsion cosmetic or dermatologic composition |
| 10/30/2001 | CA2150617C Nanoerythrosome as bioactive agent carrier |
| 10/30/2001 | CA2090700C Modified antibodies with controlled clearance time |
| 10/25/2001 | WO2001079538A2 Cell-binding nucleic acid molecules (aptamers) |
| 10/25/2001 | WO2001079524A2 Tissue-specific and pathogen-specific toxic agents, ribozymes, dnazymes and antisense oligonucleotides, and methods of use thereof |
| 10/25/2001 | WO2001079480A1 Albumin fusion proteins |
| 10/25/2001 | WO2001079444A2 Albumin fusion proteins |
| 10/25/2001 | WO2001079443A2 Albumin fusion proteins |
| 10/25/2001 | WO2001079442A2 Albumin fusion proteins |
| 10/25/2001 | WO2001079271A1 Albumin fusion proteins |
| 10/25/2001 | WO2001079258A1 Albumin fusion proteins |
| 10/25/2001 | WO2001079244A1 Pharmaceutical dopamine glycoconjugate compositions and methods of their preparation |
| 10/25/2001 | WO2001079114A2 Salt comprising more than 95 wt. % of sodium chloride, use and preparation method thereof and method for measuring salt water content |
| 10/25/2001 | WO2001078787A2 Lipopolysaccharide-conjugate vaccine for sepsis treatment |
| 10/25/2001 | WO2001078786A2 High affinity peptide-containing nanoparticles |
| 10/25/2001 | WO2001078785A2 Active substance conjugates with intracellularly active ligands |
| 10/25/2001 | WO2001078784A1 Aqueous-prodrug compound comprising moiety of paclitxel or derivatives thereof, method of preparing same and pharmaceutical composition comprising same |
| 10/25/2001 | WO2001078768A2 Targeted vaccine delivery systems |
| 10/25/2001 | WO2001078756A2 Agent for postoperative use after the removal of bone tumours |
| 10/25/2001 | WO2001078748A2 Immunomodulatory methods using carbohydrate antigens |
| 10/25/2001 | WO2001078746A1 Respiratory compositions |
| 10/25/2001 | WO2001078743A1 Medical combinations comprising tiotropium and mometasone |
| 10/25/2001 | WO2001078742A1 Medical combination comprising salmeterol and budesonide |
| 10/25/2001 | WO2001078741A1 Medical combinations comprising tiotropium and budesonide |
| 10/25/2001 | WO2001078740A1 Medical combinations comprising mometasone and salmeterol |
| 10/25/2001 | WO2001078739A1 Medical combinations comprising tiotropium and fluticasone proprionate |
| 10/25/2001 | WO2001078738A1 Medical compositions comprising (r,r)-formoterol and rofleponide |
| 10/25/2001 | WO2001078736A1 Medical combinations comprising tiotropium and rofleponide |
| 10/25/2001 | WO2001078735A1 Medicaments for treating respiratory disorders comprising formoterol and fluticasone |
| 10/25/2001 | WO2001078732A1 Ciprofloxacin infusion solutions having a good storage stability |
| 10/25/2001 | WO2001078731A1 Ciprofloxacin infusion solutions with improved storage life |
| 10/25/2001 | WO2001078730A1 Methods and compositions useful in enhancing oxygen delivery to cells |
| 10/25/2001 | WO2001078727A1 Topical formulations for the transdermal delivery of niacin and methods of treating hyperlipidemia |
| 10/25/2001 | WO2001078724A1 Rapid-onset formulation of a selective cyclooxigenase-2 |
| 10/25/2001 | WO2001078706A2 Treatment of hyperproliferative, inflammatory and related mucocutaneous disorders using inhibitors of mevalonate synthesis and metabolism |
| 10/25/2001 | WO2001078696A2 Formulations for use in inhaler devices |
| 10/25/2001 | WO2001078695A2 Pharmaceutical formulations for dry powder inhalers |
| 10/25/2001 | WO2001078694A2 Formulations for use in inhaler devices |
| 10/25/2001 | WO2001078693A2 Pharmaceutical formulations for dry powder inhalers in the form of hard-pellets |
| 10/25/2001 | WO2001078692A2 Membrane delivery system |
| 10/25/2001 | WO2001078690A1 Patch containing anti-inflammatory agent |
| 10/25/2001 | WO2001078688A1 Hydrophilic/lipophilic polymeric matrix dosage formulation |
| 10/25/2001 | WO2001078683A2 Sustained release formulations comprising growth hormone |
| 10/25/2001 | WO2001078682A2 Sustained release drug compositions |
| 10/25/2001 | WO2001078680A2 Pharmaceutical compositions comprising fluvastatin |
| 10/25/2001 | WO2001078678A1 Pre-formed sheet devices suitable for topical application |
| 10/25/2001 | WO2001078662A1 Hair growth stimulant compositions with sustained action |
| 10/25/2001 | WO2001078660A2 Topical micronutrient delivery system and uses thereof |
| 10/25/2001 | WO2001078529A2 Compositions and methods for improving vascular health |
| 10/25/2001 | WO2001027099A3 Bicyclic compounds composition and method for stabilizing the same |
| 10/25/2001 | WO2001024765A3 Antigenic modification of polypeptides |
| 10/25/2001 | WO2001021154A3 Surface modified particulate compositions of biologically active substances |
| 10/25/2001 | WO2001007013A3 Thioamide moiety-containing polymer drug conjugates |
| 10/25/2001 | WO2001000245A3 HUMANIZED ANTI-ErbB2 ANTIBODIES AND TREATMENT WITH ANTI-ErbB2 ANTIBODIES |
| 10/25/2001 | US20010034440 Complexing the target cell with therapeutic agent; antiproliferative agent |
| 10/25/2001 | US20010034363 Water soluble paclitaxel derivatives |
| 10/25/2001 | US20010034358 Human immunodeficiency syndrone, hepatitis virus |
| 10/25/2001 | US20010034349 Methods of hydrating mucosal surfaces |
| 10/25/2001 | US20010034339 For eyes, ears or noses |
| 10/25/2001 | US20010034333 Cyclodextrin polymer compositions for use as drug carriers |
| 10/25/2001 | US20010034324 Immunostimulation |
| 10/25/2001 | US20010034035 Amino acid sequences derived partially from ependymin that binds with calcium; stroke and other neurodegenerative diseases; antiischemic agents; cognition activators; conjugated to transfer through blood-brain barrier |
| 10/25/2001 | US20010033870 A combination of an estrogen and progestin for female hormoe replacement therapy, to provide contraception; minimizes skin damage, irritation or sensitization |
| 10/25/2001 | US20010033866 Sustained release oral formulations |
| 10/25/2001 | US20010033865 Melt-extrusion multiparticulates |
| 10/25/2001 | US20010033864 Low dose entecavir formulation and use |
| 10/25/2001 | US20010033845 Therapeutic composition comprising an antigen or an in vivo generator of a compound comprising an amino acid sequence |
| 10/25/2001 | US20010033843 Containing algae extract; antiseptic solution |
| 10/25/2001 | US20010033838 Animal derived lipid |
| 10/25/2001 | US20010033837 Mixture containing stabilizer |
| 10/25/2001 | US20010032643 Closure-cap and container as a two-chamber cartridge for nebulisers for producing aerosols and active substance formulations, suitable for storage |